The Hillman Letter
Publishes 1 feed
The Hillman Letter
Frontier biotech, FDA regulatory strategy, and the operator playbook. Written from Dallas by Andrew Jonathan Hillman, principal of Hillman Ventures. Monthly. Free to read.
10 posts · theirs
Lately
The Permission Gap
Direct Biologics kills ExoFlo perianal fistula trial after enrolling five patients
The False Claims Act Is the Biggest Compliance Risk in Healthcare. Most Programs Are Not Built for It.
Paradigm Peptides Was the Warm-Up. The Tissue Grey Market Is the Real Target.
The CMC chasm. Why most biotech IND submissions fail at chemistry, not biology.
What "non-toxic cancer treatment" actually means
Why family offices beat venture capital on early biotech. And where venture still wins.
When RMAT designation actually helps you. And when it is a marketing pin.
Voltage-gated sodium channels in cancer. The biology, explained for non-scientists.
Your stage-4 second opinion checklist (no fluff)
Everything on this page was read from markup The Hillman Letter published — a rel="me" link, an h-card, or the feed’s own author element. Nothing was inferred from anywhere else. To correct or remove it, get in touch. Machine-readable: JSON